Agios Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 84 to 91 Monday.
When looking for the best stocks to buy and watch, keep a close on eye on relative price strength. IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves.
Looking For Winning Stocks? Try This Simple Routine
Is Agios Pharmaceuticals Stock A Buy?
Agios Pharmaceuticals stock has been rallying this year, up 47% so far this year as of Monday. Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to establish and enter a buy zone in heavy volume.
The biotech company posted 0% earnings growth in its most recent report, while sales growth came in at 65%.
Agios Pharmaceuticals stock earns the No. 70 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm, Neurocrine Biosciences and Alkermes are among the top 5 highly rated stocks within the group.
